Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094054 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yu Jung Heo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Science, Ajou University School of Medicine, Suwon 16499, Republic of Korea. Hauptthemen laut MEDLINE: Oxidative Stress, Glucosides, Nuclear Respiratory Factor 1, Benzhydryl Compounds. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Empagliflozin (EMPA)—a sodium-glucose cotransporter type 2 inhibitor—reduces endoplasmic reticulum (ER) stress, oxidative stress, and inflammation during metabolic dysfunction-associated steatotic liver disease (MASLD) progression. However, the direct effects of EMPA on hepatic lipid metabolism and oxidative stress are unclear. Through the current study, we seek to explore the effects of EMPA on oxidative stress and related mechanisms in MASLD. To this end, MASLD was induced in C57BL/6J mice using a high-fat diet (HFD); nuclear respiratory factor 1 (NRF1) was downregulated via viral transduction (AAV8-shNrf1). Glucose homeostasis and liver histology were assessed, and oxidative stress and inflammation were measured. HFD-fed mice-derived liver tissue samples exhibited more lipid droplets, higher triglyceride levels, and elevated oxidative and ER stress than chow diet (CD)-fed mice. EMPA attenuated HFD-induced liver oxidative and ER stress. Additionally, the HFD significantly decreased NRF1 and Sirtuin (SIRT)7 expression compared with CD, which was rescued by EMPA treatment. However, these results did not affect insulin resistance or lipid synthesis-related changes upon EMPA treatment in the Nrf1-knockdown mice. Furthermore, EMPA alleviated HFD-induced hepatic steatosis and oxidative stress; however, these effects were lost in Nrf1-knockdown mice. Collectively, the results of this study suggest that EMPA ameliorates MASLD by reducing steatosis and attenuating oxidative stress via NRF1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Science, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
- Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
ORCID-Profile: Seung Jin Han, Dae Jung Kim, Kwan Woo Lee, Hae Jin Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Heo, Y. J., Park, J., Lee, N., Choi, S. E., Jeon, J. Y., Han, S. J., Kim, D. J., Lee, K. W., & Kim, H. J. (2025). Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094054
Vancouver
Heo YJ, Park J, Lee N, Choi SE, Jeon JY, Han SJ, et al. Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094054
BibTeX
@article{Heo2025,
author = {Heo, Yu Jung and Park, Jieun and Lee, Nami and Choi, Sung-E and Jeon, Ja Young and Han, Seung Jin and Kim, Dae Jung and Lee, Kwan Woo and Kim, Hae Jin},
title = {Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094054}
}
EUVIMED